References
- Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369(9579):2106–2120. doi:https://doi.org/10.1016/S0140-6736(07)60983-0.
- Attiyeh EF, London WB, Mossé YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243–2253. doi:https://doi.org/10.1056/NEJMoa052399.
- Spitz R, Hero B, Simon T, et al. Loss in Chromosome 11q Identifies Tumors with Increased Risk for Metastatic Relapses in Localized and 4S Neuroblastoma. Clin Cancer Res. 2006;12(11):3368–3373. doi:https://doi.org/10.1158/1078-0432.CCR-05-2495.
- Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. JCO. 2009;27(2):289–297. doi:https://doi.org/10.1200/JCO.2008.16.6785.
- de la Motte Rouge T, Pautier P, Genestie C, et al. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. Gynecol Oncol. 2016;142(3):452–457. doi:https://doi.org/10.1016/j.ygyno.2016.07.005.
- Zhang Q, Qu H, Sun G, et al. Early postoperative tumor marker responses provide a robust prognostic indicator for N3 stage gastric cancer. Medicine (Baltimore). 2017;96:e7560. doi:https://doi.org/10.1097/MD.0000000000007560.
- O'Neill AF, Xia C, Krailo MD, et al. α-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer. 2019;125(20):3649–3656. doi:https://doi.org/10.1002/cncr.32363.
- Massaron S, Seregni E, Luksch R, et al. Neuron-specific enolase evaluation in patients with neuroblastoma. Tumour Biol. 1998;19(4):261–268. doi:https://doi.org/10.1159/000030016.
- Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35(22):2580–2587. doi:https://doi.org/10.1200/JCO.2016.72.0177.
- Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:125–143. doi:https://doi.org/10.1007/978-94-017-7215-0_9.
- Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 2003;39(13):1899–1903. doi:https://doi.org/10.1016/s0959-8049(03)00376-9.
- Zeltzer PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer. 1986;57(6):1230–1234. doi:https://doi.org/10.1002/1097-0142(19860315)57:6 < 1230::aid-cncr2820570628 > 3.0.co;2-#.
- Cangemi G, Reggiardo G, Barco S, et al. Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther. 2012;5:417–423. doi:https://doi.org/10.2147/OTT.S36366.
- Yang S, Cai S, Ma X, et al. Discrimination of histopathologic types of childhood peripheral neuroblastic tumors based on clinical and biological factors. Sci Rep. 2018;8(1):10924. doi:https://doi.org/10.1038/s41598-018-29382-x.
- Georgantzi K, Skoldenberg EG, Stridsberg M, et al. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors. Pediatr Hematol Oncol. 2018;35(2):156–165. doi:https://doi.org/10.1080/08880018.2018.1464087.
- Lee JW, Son MH, Cho HW, et al. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2018;65(10):e27257. doi:https://doi.org/10.1002/pbc.27257. Epub 2018 May 24.
- Su Y, Wang L, Wang X, et al. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma. Cancer Med. 2019;8(4):1558–1566. doi:https://doi.org/10.1002/cam4.2045. Epub 2019 Feb 21.